A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)
Clinical trial NCT06269107 · COMPLETED
Trial details
- NCT number
- NCT06269107
- Sponsor
- Novo Nordisk A/S
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-15
- Primary completion
- 2025-05-27
- Enrollment
- 485
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.